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adjusting for age, BMI, lifestyle, and other CVD risk factors. CVD risk was 
highest among women with GDM and subsequent T2D (HR=4.13, CI=1.92, 
8.89), and attenuated among women reporting GDM without T2D (HR=1.29, 
CI=0.93, 1.79), compared with no diabetes. Associations were stable regard-
less of time since pregnancy and were similar for MI and stroke. Subgroup 
analyses indicated a stronger CVD risk among currently obese participants 
(BMI≥30) (HR=1.81, CI=1.18, 2.76) than non-obese patients (RR=1.05; 95% 
CI=0.67, 1.65). Additionally, among women with a family history of MI, 
GDM was associated with a 78% greater MI risk (CI=1.01, 3.12), and among 
those with a family history of stroke, with a nearly 4-fold greater stroke risk 
(HR=3.98, CI=1.21, 13.13). Overall, GDM was associated with CVD later in 
life, particularly among women with intermediate T2D or a family history of 
CVD. Studies are needed to confi rm these fi ndings and to identify lifestyle 
factors to mitigate CVD risk among these high risk women. 
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Maternal hyperglycemia and obesity during pregnancy contribute to new-
born adiposity as demonstrated by the Hyperglycemia and Adverse Preg-
nancy Outcome (HAPO) Study and other studies. Mechanisms underlying 
these associations are unclear, but these maternal phenotypes likely affect 
the intrauterine metabolic milieu, with metabolic signatures that affect fetal 
growth. To characterize the intrauterine environment and investigate asso-
ciations with newborn anthropometrics, we sampled 400 mothers and new-
borns of Northern European ancestry from the HAPO Study to span the range 
of maternal BMI and glucose as well as newborn birth weight (BW) and sum 
of skinfold (SSF) measurements observed in HAPO. We applied biochemical 
analyses of conventional clinical metabolites, targeted metabolomics as-
says of amino acids and acylcarnitines, and non-targeted gas-chromatogra-
phy/mass-spectrometry assays to analyze fasting and 1-hr serum in mothers 
from an oral glucose tolerance test at 28 weeks’ gestation and stored cord 
blood samples from the newborns. After Benjamini-Hochberg adjustment, 
35 metabolites demonstrated a signifi cant positive or negative association 
with maternal BMI in the fasting and/or 1 hr samples. In contrast, only 8 
metabolites were positively or negatively associated with maternal fasting 
and/or 1 hr glucose. Palmitoleate, a common mono-unsaturated fatty acid, 
was the only metabolite associated with both phenotypes. Maternal BMI 
was associated with ketones, triglycerides, and carnitine esters of ketones 
and medium- and long-chain fatty acids, while maternal glucose was as-
sociated with the gluconeogenic precursors lactate and alanine and laurate, 
a medium-chain fatty acid. Of the maternal metabolites, only the carnitine 
ester of ketones was associated with newborn SSF and BW. In summary, 
maternal BMI and glucose are associated with unique metabolic signatures 
with one metabolite also associated with newborn adiposity. 
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We have developed a computer-based smart telemedicine system to give 
automated support to GD patients while insulin is not required. The system 
combines a platform for remote monitoring of diabetes-related parameters 
with a decision-support system based on expert knowledge that generates 
automatic feedback to patients. Blood glucose (BG) data downloaded to 
the system from the patient’s glucose meter is automatically classifi ed into 
mealtime intervals and timing of measurement (preprandial, postprandial) by 
a classifi er based on a decision tree.
After downloading BG data and informing on ketonuria fasting status, the 
patient immediately receives an evaluation of the data including complete-
ness and, if needed, a proposal of diet adjustment. In case insulin therapy is 
advised, the system also contacts the responsible doctor who schedules a 
face-to-face appointment.
Sixty-nine patients diagnosed of GD following the NDDG criteria were 
randomized (2:1) to use the system (active group) and to download BG data 
every three days or to attend the usual weekly visits (control group).
At baseline, groups were comparable regarding all the clinical variables 
tested. During the follow-up period (36 days (1-141)), no correction of the 
automated-proposed treatment was done by doctors. Mean number of BG 
downloads by patient was 10.2±8 (1-29) and the mean number of changes in 
diet automatically proposed was 0.46. Mean number of BG values/day, mean 
BG and the % of BG values above 140 mg/dl, pre-partum HbA1c, and all the 
perinatal outcomes tested were similar between the groups. Mean number 
of face-to-face visits performed including fi rst visit and training was 4.8±2.8 
for the control group and 1.4±0.6 for the active group (p<0.001).
In conclusion, this computer-based smart telemedicine system success-
fully replaced face-to-face follow-up visits in women diagnosed of GD while 
insulin therapy was not required. 
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Excess Gestational Weight Gain Associated with Greater Accrual 
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Gestational weight gain (GWG) alters maternal body composition, but the 
impact of excess GWG specifi c to fat and lean body mass accrual is unclear. 
We conducted a secondary analysis of 49 overweight/obese women to mea-
sure maternal body composition changes with GWG. In early (13-16 weeks) 
and late (34-36 weeks) pregnancy, maternal height and weight, and body 
composition (using BOD POD) were assessed. We measured correlations be-
tween GWG and change in maternal lean body mass (ΔLBM) and fat mass 
(ΔFM), and compared ΔLBM and ΔFM by adherence to 2009 IOM GWG guide-
lines. We then used linear regression to explore associations between ΔFM 
and: maternal lipids, insulin sensitivity (ISogtt), scored activity and nutri-
tion questionnaires. Mean BMI was 32.4+6.1 kg/m2; women gained 9.3+5.8 
kg. Overweight, vs. obese, women were equally likely to have excess GWG 
(48% vs. 35%, p=0.6). ΔLBM was correlated with GWG (r2=0.52, p=0.001). 
ΔLBM was similar whether excess or adequate GWG. ΔFM was correlated 
with GWG (r2=0.87, p<0.001). Women with excess, vs. adequate, GWG had 
greater ΔFM (8.4+1.7 vs. 6.0+3.4 kg, p<0.001). ΔFM was not associated with 
change in fasting lipid profi le, ISogtt, physical activity, or dietary quantity or 
composition. Excess GWG is associated primarily with maternal FM but not 
LBM accrual. Future research must evaluate maternal factors, other than 
those assessed here, to explain our fi ndings and explore implications.
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Despite the importance of identifying glucokinase monogenic diabetes 
(GCK-MODY) in pregnancy, universal genetic testing is not yet practicable. 
Standard pre-genetic screening criteria (SSC) are well established. New 
pregnancy-specifi c screening criteria (NSC) were recently proposed to iden-
tify gestational diabetes (GDM) cases that should be tested for GCK-MODY. 
The NSC (fasting glucose ≥5.5mmol/L and pre-pregnancy BMI <25kg/m2) 
were derived from a predominantly Anglo-Celtic population. Its applicability 
to other ethnicities has not been examined.
To test this, we used an enrichment strategy to identify cases of GCK-
MODY, previously diagnosed as GDM. A multiethnic GDM database with 
post-partum data from 776 women was used to identify 63 women whose 
post-partum OGTT was highly suggestive of GCK-MODY by SSC. 31/63 agreed 
